Drug Therapy in the Heart Transplant Recipient

This publication has 30 references indexed in Scilit:

• Cardiac allograft vasculopathy
  Current Opinion in Cardiology, 2000
• Post-Transplant Malignancy
  Drug Safety, 2000
• SAFETY, TOLERABILITY AND EFFICACY OF CYCLOSPORINE MICROEMULSION IN HEART TRANSPLANT RECIPIENTS: A RANDOMIZED, MULTICENTER, DOUBLE-BLIND COMPARISON WITH THE OIL BASED FORMULATION OF CYCLOSPORINE - RESULTS AT SIX MONTHS AFTER TRANSPLANTATION1,2
  Transplantation, 1999
• A RANDOMIZED ACTIVE-CONTROLLED TRIAL OF MYCOPHENOLATE MOFETIL IN HEART TRANSPLANT RECIPIENTS1
  Transplantation, 1998
• RESULTS OF THE DOUBLE-BLIND, RANDOMIZED, MULTICENTER, PHASE III CLINICAL TRIAL OF THYMOGLOBULIN VERSUS ATGAM IN THE TREATMENT OF ACUTE GRAFT REJECTION EPISODES AFTER RENAL TRANSPLANTATION1,2
  Transplantation, 1998
• Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients
  The Lancet, 1997
• RANDOMIZED CLINICAL TRIAL OF ANTITHYMOCYTE GLOBULIN INDUCTION IN RENAL TRANSPLANTATION COMPARING A FIXED DAILY DOSE WITH DOSE ADJUSTMENT ACCORDING TO T CELL MONITORING
  Transplantation, 1995
• COMPARATIVE POLYCLONAL ANTITHYMOCYTE GLOBULIN AND ANTILYMPHOCYTE/ANTILYMPHOBLAST GLOBULIN ANTI-CD ANTIGEN ANALYSIS BY FLOW CYTOMETRY
  Transplantation, 1995
• THE OKT3 IMMUNOSUPPRESSIVE EFFECT
  Transplantation, 1990
• Systemic Reaction to the Anti–T-Cell Monoclonal Antibody OKT3 in Relation to Serum Levels of Tumor Necrosis Factor and Interferon-α
  New England Journal of Medicine, 1989